Steven Cohen Amylyx Pharmaceuticals, Inc. Transaction History
Point72 Asset Management, L.P.
- $51 Billion
- Q3 2025
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 2,790,066 shares of AMLX stock, worth $35.4 Million. This represents 0.07% of its overall portfolio holdings.
Number of Shares
2,790,066
Previous 4,536,266
38.49%
Holding current value
$35.4 Million
Previous $29.1 Million
30.4%
% of portfolio
0.07%
Previous 0.07%
Shares
12 transactions
Others Institutions Holding AMLX
# of Institutions
183Shares Held
94.1MCall Options Held
421KPut Options Held
174K-
Perceptive Advisors LLC New York, NY8.95MShares$114 Million0.27% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA6.82MShares$86.5 Million0.16% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA6.24MShares$79.2 Million9.51% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.27MShares$66.9 Million0.0% of portfolio
-
Saturn V Capital Management LLC Austin, TX4.6MShares$58.4 Million13.72% of portfolio
About Amylyx Pharmaceuticals, Inc.
- Ticker AMLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,533,200
- Market Cap $743M
- Description
- Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...